Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

<p>WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code for SYFOVRE will become […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/apellis-receives-permanent-j-code-j2781-for-syfovre-pegcetacoplan-injection-effective-october-1-2023/">Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>